ArticlePostepy psychiatrii neurologii2022
ANTI-NMDA-R encephalitis: case report.
Article in Postepy psychiatrii neurologii, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Anti-N-methyl-D-aspartate receptor encephalitis (NMDA-R) is the most common among autoimmune encephalitis caused by antibodies developed against surface antigens. It was first identified in 2007 as presenting with seizures, autonomic dysfunction and movement disorders, in addition to acute or subacute onset of neuropsychiatric symptoms. Multifocal, nonspecific white matter lesions can be seen on cranial magnetic resonance imaging (MRI). Since paraneoplasia is usually found in the etiology, malignancy should be screened in patients with NMDA-R encephalitis. Case description: In our case, a 48-year-old patient is presented who has been diagnosed with anti-NMDA-R encephalitis during the examinations, complaining of numbness on the left side of his face, seizures, imbalance, excessive talkativeness and insomnia. Comment: Autoimmune encephalitis should be considered in patients with suspected autoimmune encephalitis, which takes severe clinical course and fails to respond to treatment adequately; NMDA receptor antibodies and other autoantibody tests should be requested, malignancy screening should be performed and treatment should be started in the early period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.